Modality
Multispecific
MOA
FXIai
Target
KRASG12C
Pathway
Amyloid
T2D
Development Pipeline
Preclinical
Dec 2017
→ Jun 2030
PreclinicalCurrent
NCT07744698
2,356 pts·T2D
2017-12→2030-06·Completed
NCT06279487
2,048 pts·T2D
2019-12→2027-12·Recruiting
4,404 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-12-151.7y awayInterim· T2D
2030-06-134.2y awayInterim· T2D
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Complet…
Preclinical
Recruit…
Catalysts
Interim
2027-12-15 · 1.7y away
T2D
Interim
2030-06-13 · 4.2y away
T2D
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07744698 | Preclinical | T2D | Completed | 2356 | ORR |
| NCT06279487 | Preclinical | T2D | Recruiting | 2048 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C |